Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Latent class analysis to define radiological subgroups in pulmonary nontuberculous mycobacterial disease.

Cowman SA, Jacob J, Obaidee S, Andres Floto R, Wilson R, Haworth CS, Loebinger MR.

BMC Pulm Med. 2018 Aug 31;18(1):145. doi: 10.1186/s12890-018-0675-8.

2.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

3.

British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA.

BMJ Open Respir Res. 2017 Oct 19;4(1):e000242. doi: 10.1136/bmjresp-2017-000242. eCollection 2017. Review.

4.

Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.

Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017. Print 2018 Jan. No abstract available.

PMID:
29326319
5.

Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Haworth CS, Floto RA.

Thorax. 2017 Nov;72(11):969-970. doi: 10.1136/thoraxjnl-2017-210929.

PMID:
29054887
6.

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA.

Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927. Review. No abstract available.

PMID:
29054853
7.

European Respiratory Society guidelines for the management of adult bronchiectasis.

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep.

PMID:
28889110
8.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

PMID:
28596426
9.

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.

Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, Walshaw MJ, Williams D, Fothergill JL, De Soyza A, Winstanley C.

Eur Respir J. 2017 Apr 26;49(4). pii: 1602108. doi: 10.1183/13993003.02108-2016. Print 2017 Apr.

10.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

Plant BJ, Downey DG, Eustace JA, Gunaratnam C, Haworth CS, Jones AM, McKone EF, Peckham DG, Ketchell RI, Bilton D.

J Cyst Fibros. 2017 Nov;16(6):695-701. doi: 10.1016/j.jcf.2017.02.006. Epub 2017 Apr 6.

11.

Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases.

van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET.

Eur Respir J. 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb. No abstract available.

12.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

13.

Bone health and disease in cystic fibrosis.

Marquette M, Haworth CS.

Paediatr Respir Rev. 2016 Aug;20 Suppl:2-5. doi: 10.1016/j.prrv.2016.06.003. Epub 2016 Jun 21. Review.

PMID:
27461283
14.

Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF).

Viviani L, Harrison MJ, Zolin A, Haworth CS, Floto RA.

J Cyst Fibros. 2016 Sep;15(5):619-23. doi: 10.1016/j.jcf.2016.03.002. Epub 2016 Apr 1.

15.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

16.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

Thorax. 2016 Jan;71 Suppl 1:i1-22. doi: 10.1136/thoraxjnl-2015-207360.

17.

The growing threat of nontuberculous mycobacteria in CF.

Floto RA, Haworth CS.

J Cyst Fibros. 2015 Jan;14(1):1-2. doi: 10.1016/j.jcf.2014.12.002. Epub 2014 Dec 6. No abstract available.

18.

A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis.

Bhattacharyya SB, Calado F, Priedane E, Shirore RM, Haworth CS, Flume PA, Sonathi V, Thomas SK.

Value Health. 2014 Nov;17(7):A551. doi: 10.1016/j.jval.2014.08.1799. Epub 2014 Oct 26. No abstract available.

19.

Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions.

Haworth CS, Bilton D, Elborn JS.

Respir Med. 2014 Oct;108(10):1397-408. doi: 10.1016/j.rmed.2014.09.005. Epub 2014 Sep 16. Review.

20.

Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D.

Am J Respir Crit Care Med. 2014 Apr 15;189(8):975-82. doi: 10.1164/rccm.201312-2208OC.

21.

Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.

Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA.

Lancet. 2013 May 4;381(9877):1551-60. doi: 10.1016/S0140-6736(13)60632-7. Epub 2013 Mar 29.

22.

Non-tuberculous mycobacteria in cystic fibrosis.

Hill UG, Floto RA, Haworth CS.

J R Soc Med. 2012 Jun;105 Suppl 2:S14-8. doi: 10.1258/jrsm.2012.12s003. Review. No abstract available.

23.

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.

Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson ME, Conway SP, Etherington C, Elborn JS, Rendall J, Wheaton E, Kadri E, Elliott J, Barker HC, Bearcroft PW, Hlaing T, Compston JE.

J Cyst Fibros. 2011 Dec;10(6):470-6. doi: 10.1016/j.jcf.2011.07.007. Epub 2011 Aug 16.

24.

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA.

J Clin Invest. 2011 Sep;121(9):3554-63. doi: 10.1172/JCI46095. Epub 2011 Aug 1.

25.

European cystic fibrosis bone mineralisation guidelines.

Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE, Conway SP, Castanet M, Wolfe S, Haworth CS.

J Cyst Fibros. 2011 Jun;10 Suppl 2:S16-23. doi: 10.1016/S1569-1993(11)60004-0.

26.

Impact of cystic fibrosis on bone health.

Haworth CS.

Curr Opin Pulm Med. 2010 Nov;16(6):616-22. doi: 10.1097/MCP.0b013e32833e2e94. Review.

PMID:
20739891
27.

Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis.

Shead EF, Haworth CS, Barker H, Bilton D, Compston JE.

J Cyst Fibros. 2010 Mar;9(2):93-8. doi: 10.1016/j.jcf.2009.11.007. Epub 2009 Dec 14.

28.

Diabetes as a determinant of mortality in cystic fibrosis.

Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI.

Diabetes Care. 2010 Feb;33(2):311-6. doi: 10.2337/dc09-1215. Epub 2009 Nov 16.

29.

Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation.

McKeon DJ, Cadwallader KA, Idris S, Cowburn AS, Pasteur MC, Barker H, Haworth CS, Bilton D, Chilvers ER, Condliffe AM.

Eur Respir J. 2010 Jun;35(6):1264-72. doi: 10.1183/09031936.00089709. Epub 2009 Oct 19.

30.

Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.

Gillham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE.

J Antimicrob Chemother. 2009 Apr;63(4):728-32. doi: 10.1093/jac/dkp007. Epub 2009 Feb 4.

PMID:
19193658
31.

Clostridium difficile pancolitis in adults with cystic fibrosis.

Barker HC, Haworth CS, Williams D, Roberts P, Bilton D.

J Cyst Fibros. 2008 Sep;7(5):444-7. doi: 10.1016/j.jcf.2008.02.007. Epub 2008 Jun 27.

32.

Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults.

Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D.

Diabetes Care. 2008 Sep;31(9):1789-94. doi: 10.2337/dc08-0466. Epub 2008 Jun 5.

33.

A single centre experience of liver disease in adults with cystic fibrosis 1995-2006.

Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ.

J Cyst Fibros. 2008 May;7(3):252-7. Epub 2007 Nov 26.

34.

Characteristics of adults with and without cystic fibrosis-related diabetes.

Adler AI, Gunn E, Haworth CS, Bilton D.

Diabet Med. 2007 Oct;24(10):1143-8.

PMID:
17888134
35.

Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone.

Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE.

Thorax. 2007 Jul;62(7):650-1. No abstract available.

36.

Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics.

Fowler SJ, French J, Screaton NJ, Foweraker J, Condliffe A, Haworth CS, Exley AR, Bilton D.

Eur Respir J. 2006 Dec;28(6):1204-10. Epub 2006 Jun 28. Erratum in: Eur Respir J. 2007 Mar;29(3):614-5.

37.

Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis.

Shead EF, Haworth CS, Gunn E, Bilton D, Scott MA, Compston JE.

Am J Respir Crit Care Med. 2006 Aug 1;174(3):306-11. Epub 2006 May 4.

PMID:
16675777
39.

Guide to bone health and disease in cystic fibrosis.

Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB.

J Clin Endocrinol Metab. 2005 Mar;90(3):1888-96. Epub 2004 Dec 21. Review.

PMID:
15613415
40.

Inflammatory related changes in bone mineral content in adults with cystic fibrosis.

Haworth CS, Selby PL, Webb AK, Martin L, Elborn JS, Sharples LD, Adams JE.

Thorax. 2004 Jul;59(7):613-7.

41.

A prospective study of change in bone mineral density over one year in adults with cystic fibrosis.

Haworth CS, Selby PL, Horrocks AW, Mawer EB, Adams JE, Webb AK.

Thorax. 2002 Aug;57(8):719-23.

42.

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.

Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AW, Webb AK.

Thorax. 2001 Apr;56(4):314-6.

43.

Cystic fibrosis related low bone density.

Haworth CS, Webb AK, Elkin SL, Hodson ME, Compston JE, Selby PL.

Arch Dis Child. 2000 Oct;83(4):369. No abstract available.

44.

Audit of oxygen prescribing before and after the introduction of a prescription chart.

Dodd ME, Kellet F, Davis A, Simpson JC, Webb AK, Haworth CS, Niven RM.

BMJ. 2000 Oct 7;321(7265):864-5. No abstract available.

45.

Bone histomorphometry in adult patients with cystic fibrosis.

Haworth CS, Webb AK, Egan JJ, Selby PL, Hasleton PS, Bishop PW, Freemont TJ.

Chest. 2000 Aug;118(2):434-9.

PMID:
10936137
46.

Holidays and cystic fibrosis.

Verma A, Dodd ME, Haworth CS, Webb AK.

J R Soc Med. 2000;93 Suppl 38:20-6. Review. No abstract available.

47.
48.

Low bone mineral density in adults with cystic fibrosis.

Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, McL Niven R, Economou G, Horrocks AW, Freemont AJ, Mawer EB, Adams JE.

Thorax. 1999 Nov;54(11):961-7.

49.

Hip fracture and bone histomorphometry in a young adult with cystic fibrosis.

Haworth CS, Freemont AJ, Webb AK, Dodd ME, Selby PL, Mawer EB, Adams JE.

Eur Respir J. 1999 Aug;14(2):478-9.

50.

Supplemental Content

Loading ...
Support Center